Dementia in Parkinson’s disease

Lewy body dementia includes Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB), and is the second most common form of dementia after Alzheimer’s disease (AD). Both conditions share significant phenotypic and pathological signatures but differ in terms of whether Parkinsonian symp...

Full description

Bibliographic Details
Main Authors: Hu, M, Baig, F
Other Authors: Geddes, JR
Format: Book section
Language:English
Published: Oxford University Press 2020
_version_ 1797112427349803008
author Hu, M
Baig, F
author2 Geddes, JR
author_facet Geddes, JR
Hu, M
Baig, F
author_sort Hu, M
collection OXFORD
description Lewy body dementia includes Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB), and is the second most common form of dementia after Alzheimer’s disease (AD). Both conditions share significant phenotypic and pathological signatures but differ in terms of whether Parkinsonian symptoms appear first (PDD) or after/the same time as cognitive symptoms (DLB). In the United Kingdom, over 100,000 people are affected, with numbers predicted to double by 2050. Average care costs per patient are more than double those of AD, reflecting the associated multi-morbidity and unmet therapeutic needs. PDD has a long-term cumulative prevalence of 80% and major consequences for independence, nursing home admission, psychiatric comorbidity, caregiver burden, and mortality. Consequently, there is interest in a potential transition stage—Parkinson’s disease with mild cognitive impairment (PD-MCI)—to identify those at increased risk for PDD, to facilitate intervention studies. Advances in both symptomatic and disease-modifying treatments have so far been limited. Future research must address patient-specific factors influencing variability in treatment response and progression to be effective.
first_indexed 2024-03-07T08:25:37Z
format Book section
id oxford-uuid:09fd4b8c-b47e-456b-940a-bc62bc875c7b
institution University of Oxford
language English
last_indexed 2024-03-07T08:25:37Z
publishDate 2020
publisher Oxford University Press
record_format dspace
spelling oxford-uuid:09fd4b8c-b47e-456b-940a-bc62bc875c7b2024-02-15T15:42:52ZDementia in Parkinson’s diseaseBook sectionhttp://purl.org/coar/resource_type/c_1843uuid:09fd4b8c-b47e-456b-940a-bc62bc875c7bEnglishSymplectic Elements at OxfordOxford University Press2020Hu, MBaig, FGeddes, JRAndreasen, NCGoodwin, GMLewy body dementia includes Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB), and is the second most common form of dementia after Alzheimer’s disease (AD). Both conditions share significant phenotypic and pathological signatures but differ in terms of whether Parkinsonian symptoms appear first (PDD) or after/the same time as cognitive symptoms (DLB). In the United Kingdom, over 100,000 people are affected, with numbers predicted to double by 2050. Average care costs per patient are more than double those of AD, reflecting the associated multi-morbidity and unmet therapeutic needs. PDD has a long-term cumulative prevalence of 80% and major consequences for independence, nursing home admission, psychiatric comorbidity, caregiver burden, and mortality. Consequently, there is interest in a potential transition stage—Parkinson’s disease with mild cognitive impairment (PD-MCI)—to identify those at increased risk for PDD, to facilitate intervention studies. Advances in both symptomatic and disease-modifying treatments have so far been limited. Future research must address patient-specific factors influencing variability in treatment response and progression to be effective.
spellingShingle Hu, M
Baig, F
Dementia in Parkinson’s disease
title Dementia in Parkinson’s disease
title_full Dementia in Parkinson’s disease
title_fullStr Dementia in Parkinson’s disease
title_full_unstemmed Dementia in Parkinson’s disease
title_short Dementia in Parkinson’s disease
title_sort dementia in parkinson s disease
work_keys_str_mv AT hum dementiainparkinsonsdisease
AT baigf dementiainparkinsonsdisease